SOT (Supportive Oligonucleotide Technique)

SOT therapy uses synthetic oligonucleotides, which are short strands of DNA or RNA engineered to bind to a specific messenger RNA (mRNA) sequence from a pathogen or abnormal cell. When the oligonucleotide binds its target mRNA, it can either block the mRNA from being translated into protein or trigger its destruction by cellular mechanisms. This prevents the production of proteins essential for the replication or survival of the targeted cells or viruses.

This therapy is tailored to each patient – and against the most active target for that individual. The SOT is designed to be highly specific for a particular target sequence found in cancer cells, viruses, or Lyme bacteria. Therefore, it is highly specific to these only and will only work for the patient that is was made for.

SOT is being investigated for its potential to interfere with the replication or function of targeted pathogens and abnormal cells, including certain types of bacteria, viruses, and cancer cells. Some laboratory and early clinical data suggest oligonucleotide therapies may have activity against circulating tumor cells and other abnormal cell types. The ability of specific SOT molecules to cross the blood-brain barrier or induce apoptosis is still under investigation and may vary depending on the target and design.

Currently, the SOT is available for
The following Lyme species and co-infections:

Borrelia mayonii – Borrelia burgdorferi – Borrelia garinii – Borrelia bissettii – Borrelia bavariensis – Borrelia miyamotoi – Candidatus Borrelia tachyglossi – Borrelia valaisiana – Borrelia afzelii – Borrelia finlandensis – Borrelia recurrentis – Bartonella henselae – Bartonella bacilliformis – Bartonella vinsonii – Bartonella quintana – Babesia microti – Babesia bigemina – Babesia divergens – Babesia duncani – Babesia bovis.

The following viruses:

– EBV (Epstein Barr Virus)
– CMV (cytomegalovirus)
– Coxsackie virus (Types A & B)
– VZV (Varicella Zoster virus (chicken pox, shingles))
– HHV1/HSV1 (oral herpes virus) – HHV2/HSV2 (genital herpes virus) – HHV6 (Types A & B) (human herpes virus 6)
– HPV (16/18) (human papillomavirus) – HPV (6/11) (human papillomavirus)
– HTLV1 (Human T-cell lymphotropic Virus)
– HBV (Hepatitis B Virus)
– HCV (Hepatitis C Virus)
– HIV (Human Immunodeficiency Virus)

Because it is highly compatible with the patient, the side effects are usually minimal. Potential side effects may include headaches, body aches, general malaise, sweating, diarrhea, cough, fever, (generally <101°F), and mild to moderate flu-like symptoms.

These symptoms resolve within 24-48 hours or up to a week.

Herxheimer reactions (also known as “die-off”) can occur.
“Herx” reactions, can include fatigue, body aches, and headache.

Patients who have gone through treatment will often say that symptoms can get worse before it gets better.

1 – The patient’s blood is drawn.
2 – The blood is sent to RGCC laboratory.
3 – RGCC lab identifies a specific gene sequence from the target pathogen or abnormal cell and creates a complementary oligonucleotide designed to bind the corresponding mRNA. This may help interfere with the production of proteins needed for the pathogen or abnormal cell to replicate or survive.
4 – RGCC ships the blood back to the patient’s clinic, where it is infused intravenously (usually takes about an hour).

Intravenous antihistamines and low dose steroids are given immediately prior to SOT administration in order to lessen the (rare) chance of allergic reaction and tighten the vein walls to minimize leaking of SOT.

SOT may be repeated up to 3x per year if needed.
With each round of SOT it is recommended to retest for the presence of pathogens.
At some point the infection may be completely eradicated or remain stable in remission.